2024-513123-17-00招募中3 期
CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIMUMAB, OR THEIR COMBINATION IN NON INFECTIOUS NON ANTERIOR UVEITIS: A MULTICENTER, RANDOMIZED, PARALLEL 3 ARMS, ACTIVE-CONTROLLED, PHASE 3 OPEN LABEL WITH BLINDED OUTCOME ASSESSMENT STUDY.
Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos21 个研究点 分布在 1 个国家目标入组 192 人开始时间: 2024年4月15日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 192
- 试验地点
- 21
- 主要终点
- Proportion of patients achieving a Good Clinical Response between the combination therapy arm and the single immunosuppressive drugs arms.
研究概览
简要总结
To compare the proportion of patients achieving a Good Clinical Response by week 16 that is maintained in every study visit until week 52
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Subjects diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis in at least one eye
- •Adult patients (≥18 years)
- •Subjects with at least one flare of active eye inflammation in the previous 180 days before Baseline visit, defined by the presence of at least 1 of the following parameters in either eye: a. Active chorioretinal or retinal vascular lesion, AND/OR b. Presence of macular edema by optical coherence tomography (OCT: thickness >350 μm when measured with spectralis or >340 μm when measured with Cirrus or TopCon, AND cysts or intraretinal fluid), AND/OR c. ≥ 2+ anterior chamber cells (ACC; SUN criteria4) , AND/OR d. ≥ 2+ vitreous haze (National Eye Institute [NEI]113/SUN criteria).
- •Subjects with active eye inflammation at Baseline visit, defined by the presence of at least 1 of the following parameters in either eye: a. Active chorioretinal or retinal vascular lesion, AND/OR b. Presence of macular edema by OCT (thickness >350 μm when measured with spectralis or >340 μm when measured with Cirrus or TopCon AND cysts or intraretinal fluid), AND/OR c. ≥ 1+ ACC, AND/OR d. ≥ 1+ vitreous haze.
- •Subjects meeting at least ONE of the following criteria: a. Subjects with known chronic condition necessitating GCs-sparing immunosuppressive treatment: multifocal choroiditis with panuveitis, serpiginous choroidopathy, birdshot retinochoroidopathy, diffuse retinal vasculitis, Vogt-Koyanagi-Harada with bullous serous retinal and/or choroidal detachments, sympathetic ophthalmia. No prior therapy is required for these patients. AND/OR b. Intermediate uveitis fulfilling the following characteristics: Bilateral disease, AND, Low visual acuity (best corrected visual acuity <0.5) OR Bilateral macular involvement, defined as presence of macular edema (as defined in Inclusion Criteria 3, subpoint (b)), macular atrophy, and/or macular scarring. No prior therapy is required for these patients. AND/OR c. Subjects with registered local/systemic corticosteroid refractory uveitis in the previous 180 days months before Baseline visit, defined as: Presence of active inflammation after 4 weeks of high-dose (1mg/kg prednisone equivalent, see equivalence Table 6) corticosteroid treatment, resulting in an incomplete response (there was an amelioration, but there is still inflammation); AND/OR, Presence of active inflammation 4 weeks after a regional corticosteroid injection; AND/OR, Treatment with oral corticosteroids resulting in a reduction of inflammation, followed by relapse [increase in ≥1 grade in ACC or vitreous haze or a change of non-active to active lesions (including chorioretinal or retinal vascular lesion and/or macular edema)] when GCs was tapered; AND/OR, Presence of active inflammation after a long-acting corticosteroid intramuscular injection administered between 4 weeks to 180 days before the Baseline visit); AND/OR, Active inflammation after treatment with >10mg/day oral prednisone for at least the past 90 days before Baseline.
- •If female, subject is: a. Not of childbearing potential: at least 1 year or more since the final menstrual period or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy); b. Of childbearing potential and willing to use an acceptable method of contraception during the study period (i.e. pharmacologics, devices, barrier methods) or abstinence, and for 150 days after the last dose of study drugs; For the purpose of this clinical trial, woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. c. Not pregnant or breastfeeding
- •Subject has a negative tuberculosis skin test (PPD test or equivalent) and non-pathological Chest X-ray (CXR; Posterior-anterior and lateral view) at Screening or in the previous 90 days before Baseline visit. If the subject has a positive PPD test (or equivalent), has had a past ulcerative reaction to PPD placement and/or a CXR consistent with prior tuberculosis (TB) exposure, the subject must initiate, be currently receiving or have documented completion of a course of prophylactic anti-TB therapy
- •Subjects able and willing to provide written informed consent and to comply with the study protocol.
- •Do not participate in another clinical trial
排除标准
- •Subjects with confirmed or suspected infectious uveitis, including ocular histoplasmosis syndrome
- •Subjects with a history of prior intraocular surgery within 30 days prior to the Baseline visit, AND/OR any planned eye surgery within the next 52 weeks from Baseline Visit
- •Subjects with best spectacle-corrected visual acuity (BCVA) worse than 20/400 (ETDRS logMAR > 1.34) in the better eye during the screening or at Baseline visit
- •Subjects with active malignancy considered by the Site’s Investigator, and confirmed or suspected ocular masquerade syndromes
- •Subjects with systemic autoimmune disease or ocular condition (besides uveitis) anticipated to dictate treatment course, as considered by the Site’s Investigator
- •Subjects with infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline visit or oral anti-infectives within 14 days prior to the Baseline visit
- •Subjects with systemic active or chronic recurring infections, such as active TB (If the subject has a positive PPD test (or equivalent), has had a past ulcerative reaction to PPD placement and/or a CXR consistent with prior tuberculosis (TB) exposure, the subject must initiate, be currently receiving or have documented completion of a course of prophylactic anti-TB therapy (see “Study Procedures” section)), syphilis, or hepatitis B or C, at Screening visit or in the previous 90 days before Baseline visit; AND/OR a history of invasive infection (e.g., listeriosis and histoplasmosis)
- •Subjects with history of moderate to severe congestive heart failure (NYHA class III or IV), recent cerebrovascular accident (6 months) and any other condition which, in the opinion of the Site’s Investigator, would put the subject at risk by participation in the study
- •Subjects with clinically significant abnormal screening laboratory results as evaluated by the Site’s Investigator (at screening/baseline or in the previous 4 weeks).
- •Central nervous system demyelinating disease: a. Subjects with history of Central nervous system demyelinating disease AND/OR b. Magnetic Resonance Imaging (MRI) findings suggestive of a demyelinating disease: All subjects with intermediate uveitis or panuveitis that have signs of intermediate uveitis (e.g., presence or history of snowbanking or snowballs) must have a brain MRI within 90 days prior to the Baseline visit.
- •Subject diagnosed with or with suspected Behçet’s disease
- •Subjects with previous intolerability, safety issues according to investigator criteria, AND/OR previous failure to control ocular or other inflammation with MTX
- •Subjects with previous exposure to any biological therapy at any time (excluding intravitreal anti-vascular endothelial growth factor [anti-VEGF] therapy and denosumab), including those with that have a potential or known association with progressive multifocal leukoencephalopathy (i.e. natalizumab, rituximab or efalizumab);
- •Subjects with previous exposure to synthetic immunosuppressive therapy (such as mycophenolate or cyclosporine) other than corticosteroids in the past 6 months before Baseline
- •Subjects with chronic structural eye damage considered by the Site’s Investigator to: a. Interfere with the measurement of any of the study outcomes, AND/OR b. Cause eye damage regardless of the inflammatory process, AND/OR c. Prevent the normalization of the eye structures
- •Chronic hypotony (IOP < 5 mm Hg for in the last 3 months and/or in the baseline visit) in both eyes
- •Subjects receiving local GCs: a. Fluocinolone acetonide implant (Iluvien®) in the previous 3 years before Baseline; b. Dexametasona implant (Ozurdex®) in the previous 6 months before Baseline; c. Removal of a GC implant in the previous 30 days before Baseline Visit; d. Intra or periocular GC injections in the previous 8 weeks before Baseline Visit;
- •Subjects receiving intravitreal anti-VEGF therapy: a. Ranibizumab or bevacizumab in the previous 45 days before Baseline Visit; b. Aflibercept in the previous 60 days before Baseline Visit;
结局指标
主要结局
Proportion of patients achieving a Good Clinical Response between the combination therapy arm and the single immunosuppressive drugs arms.
Proportion of patients achieving a Good Clinical Response between the combination therapy arm and the single immunosuppressive drugs arms.
次要结局
- Change from baseline of the HADS between groups
- Proportion of patients achieving the primary efficacy outcome based on the commercial brand of ADA prescribed
- Proportion of patients achieving the primary efficacy outcome based on the use of iv GC during the screening period
- Proportion of patients achieving a Good Clinical Response by week 16, between study arms
- Change from baseline of the VFQ-25 between groups
- Direct and indirect cost, and Incremental Cost Effectiveness Ratios
- Proportion of patients achieving each of the clinical component of the primary efficacy outcome, between study arms
- Proportion of patients achieving each clinical component of the Good Clinical Response by week 16, between study arms
- Evolution of the UVEDAI during follow-up
- Evolution of the EQ-5D during follow-up
- Time to inflammatory relapse between groups, defined as the time from visit 16 weeks until end of the study, loss of follow-up or appearance of at least one of the following, in those individuals achieving a Good Clinical Response by visit 16 week
- Evolution of the BCVA during follow-up
- Proportion of patients developing anti-ADA antibodies (AAA) at Baseline, week 15, 27 and the FET visit, between the ADA monotherapy and the combination arm.
研究者
Investigator coordinator
Scientific
Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos
研究点 (21)
Loading locations...
相似试验
招募中
1 期
CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIMUMAB, OR THEIR COMBINATION IN NON INFECTIOUS NON ANTERIOR UVEITIS: A MULTICENTER, RANDOMIZED, PARALLEL 3 ARMS, ACTIVE-CONTROLLED, PHASE 3 OPEN LABEL WITH BLINDED OUTCOME ASSESSMENT STUDY.on-infection uveitisCTIS2024-513123-17-00Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos192
进行中（未招募）
1 期
Co-THEIA (Combination THerapy with mEthotrexate and adalImumAb for uveitis): Efficacy, safety and cost-effectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior uveitison infectious non anterior uveitisEUCTR2020-000130-18-ESFundación para la Inv. Biomédica Hospital Clínico San Carlos192
已完成
2 期
Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690MucositisNCT04046250Tosk, Inc.22
进行中（未招募）
不适用
JCOG0905:A Phase III Study Comparing Methotrexate, Adrimycin and Cisplatin (MAP) with MAP + Ifosfamide (MAP + IF) for the Treatment of Osteosarcoma (OS-MAP + IF-P3)jRCTs031180126250
已完成
4 期
IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease;A randomized clinical trial in patients with recent-onset arthritis to compare the efficacy of DMARD combination therapy including prednisone with combination therapy including adalimumab, a TNF-blocking agent.rheumatoid arthritis - rheumatic disease1000381610023213NL-OMON30362eids Universitair Medisch Centrum610